Roche Abandons Emugrobart – Clears Path for Scholar Rock’s Apitegromab to Dominate SMA

Roche halts emugrobart development, clearing path for Scholar Rock's apitegromab to dominate SMA muscle therapy market. Cantor sees multi-billion potential.